AARD - Aardvark Therapeutics, Inc. Common Stock

NYSE * Healthcare * Biotechnology

$3.78

$-0.16 (-4.06%)

About Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Price Chart

+%
Loading chart...

AARD Key Statistics

Market Cap

$83.12M

0

P/B Ratio

1.00

EPS

$-3.21

Employees

40

How AARD Compares to Peers

AARD is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

#6

of 6

CompanyP/EGrowthCompare
AARDN/A0%-
AMGN24.00%vs AMGN
GILD17.60%vs GILD
VRTX26.20%vs VRTX
REGN15.10%vs REGN
BIIB21.10%vs BIIB

Aardvark Therapeutics, Inc. Common Stock Company Information

Headquarters
4370 La Jolla Village Drive, San Diego, CA, United States, 92122, undefined
Website
aardvarktherapeutics.com
Sector
Healthcare
Industry
Biotechnology
Data Updated:
Ready to invest in AARD?

Commission-free trading available. Affiliate links.

AARD Lician Score

5% confidence
4.0/10
Neutral

AARD has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates AARDacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

AARD Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

35810Value5.0Growth2.0Quality5.0Momentum5.0Safety5.04.4/10
5.0

Value

2.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for AARD